Skip to main content

Advertisement

Table 1 Literature review of pediatric patients with vincristine induced vocal cord palsy

From: Vocal cord palsy after vincristine treatment in a child and the inefficacy of glutamic acid in the prevention of relapse: a case report

Authors Sex/age Diagnosis Duration, weeks Vocal cord palsy Airway intervention Swallowing dysfunction Associated neuropathy Subsequent vincristine administration
Tobias and Bozeman [2] M/5 years ALL 0.5 L No No No Omitted
F/2 years NHL-T 2 L No No Yes Half dose
Annino et al. [3] M/1.5 years RMS 6 BL No Yes No Omitted
M/1.3 years Ependymoma 2 BL No No No Omitted
M/3 years ALL 2 L No No Yes Half dose
Agarwall et al. [4] F/11 years LNH NA R No No No NA
Anghelescu et al. [5] NA/0.4 years ALL 1 BL Yes Yes No NA
Graf et al. [6] M/15 years ALL + CMT 34.3 BL No No Yes NA
Ahmad et al. [7] M/3 years ALL + Down’s 38.5 BL Yes Yes No Omitted
M/1.8 years Ependymoma 34.3 BL No No No Omitted
M/2 years ALL 27 BL No Yes Yes Omitted*
Kuruvilla et al. [1] F/1 year ALL 37 BL Yes Yes No Omitted
M/4 years ALL + Down’s 20 BL Yes No Yes Half dose
M/5 years ES 7 BL No No No No indication
M/3 years RMS 4 L No Yes   Half dose, then increased to regular regimen
Latiff et al. [8] M/2 years ALL 13 BL No No No Half dose**
F/3 years ALL 40 BL Yes*** No No Half dose
Naithani et al. [9] M/14 years ALL 6 BL No Yes Yes Omitted
  1. *Vincristine definitely omitted after symptoms recurrence in consequence of drug reintroduction at full dose (drug initially given at 25% of recommended dose and gradually increased to full dose)
  2. **Vincristine definitely omitted after symptoms recurrence in consequence of drug reintroduction at half dose
  3. ***Cordectomy.
  4. ALL = acute lymphoblastic leukemia; BL = bilateral; CMT = Charcot Marie Tooth; Down’s = Down’s syndrome; ES = Ewing’s sarcoma; L = left; NA = not assessed; NHL-T = T cell non-Hodgkin’s lymphoma; R = right; RMS = rhabdomyosarcoma